Could interleukin-1 antagonists be the answer to managing acute gout? Guidelines for the management of this disorder, issued by the European League Against Rheumatism (EULAR) and the British ...

A new study has uncovered an unexpected way cancer cells can escape the immune system, making it harder for treatments to ...

Interleukin-1 receptor-associated kinase 4 is critical in the modulation of inflammatory responses through Toll-like receptor and IL-1R signaling.

The Food and Drug Administration has granted Fast Track designation to GNSC-001 for the treatment of osteoarthritis of the knee.

GS-6791 is a selective, orally bioavailable degrader of interleukin-1 receptor-associated kinase 4 (IRAK4), which is being developed in collaboration with Gilead Sciences for the potential treatment ...